The creative process of discovering novel pharmaceuticals based on the understanding of a biological target is known as Drug Design, sometimes known as rational drug design or simply rational design. A protein, for example, is a frequent example of a biomolecule whose activity is activated or inhibited by the medicine, which benefits the patient therapeutically. Drug design, in its most basic sense, is creating compounds that interact with and bind to biomolecular targets that are complementary to one another in shape and charge. Computer modelling methods are commonly but not always used in drug design. Computer-aided drug design is another name for this kind of modelling. The term "Structure-Based Drug Design" refers to drug development that is based on an understanding of the biomolecular target's three-dimensional structure. In addition to small molecules, Biopharmaceuticals, such as peptides and therapeutic antibodies, are a growingly significant class of medications. Computational techniques have also been developed to enhance the affinities, selectivities, and stabilities of these protein-based treatments.
Vladlen Slepak
University of Miami School of Medicine, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Lan Wang
Paretor LLC, United States
Maria Cristina Gamberini
University of Modena and Reggio Emilia, Italy
Lucas Amaral Machado
University of Sao Paulo State – UNESP, Brazil
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, IndiaSubmit your abstract Today
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : A NAMs-compatible mechanopharmacological model of drug penetration in the urinary bladder
Kunal Sharma, Swisss Federal Institute of Technology Lausanne, Switzerland
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Integrated Raman, SERS and computational approaches for the study of bioactive molecules in pharmaceutical chemistry
Maria Cristina Gamberini, University of Modena and Reggio Emilia, Italy
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada